WK 7 - Part 4 Gastrointestinal Pharmacology: Emesis and Anti-emetic Agents

Introduction to Emesis and Anti-emetics

  • The study of gastrointestinal pharmacology emphasizes the understanding of the mechanisms of emesis (vomiting) as well as the pharmacological agents developed for the prevention and treatment of nausea and vomiting. Through an exploration of these mechanisms and treatments, healthcare providers can tailor therapeutic interventions to individual patient needs.

  • Objectives: The objectives of this lecture are to deepen the understanding of the various mechanisms underlying emesis and critically examine the pharmacology of different classes of antiemetic agents, specifically:

    • Anticholinergics

    • Sedating antihistamines

    • Dopamine receptor antagonists

    • Serotonin antagonists

    • NK1 receptor antagonists

Definitions

  • Nausea: An unpleasant, often uncomfortable sensation characterized by the feeling of impending vomiting. This sensation may stem from various physiological triggers, including hormonal changes, stress, and gastrointestinal issues.

  • Emesis (Vomiting): The forceful expulsion of stomach contents through the mouth. While emesis can serve as a protective reflex in response to noxious agents, it can also lead to significant discomfort and complications such as dehydration, electrolyte imbalances, and in severe cases, metabolic alkalosis or acidosis due to the loss of gastric acid or excessive fluid intake.

Mechanisms of Emesis

  • The process of emesis is complex and involves multiple neurotransmitters and neural pathways. Key anatomical areas include:

    • Chemoreceptor Trigger Zone (CTZ): Situated in the area postrema of the medulla oblongata, this zone is particularly sensitive to bloodborne toxins due to its proximity to the bloodstream and its ability to bypass the blood-brain barrier.

    • Vomiting Centre: Located within the medulla, this center integrates signals from various sources to coordinate the act of vomiting, demonstrating its role as a central processing hub.

    • Vestibular System: This system is responsible for maintaining balance and can trigger vomiting through mechanisms such as motion sickness or vestibular disturbances. It communicates directly with the vomiting center to elicit a response to motion-related nausea.

    • Vagal Afferents: These nerve fibers transmit signals from the gastric lining to the central nervous system, ensuring that the brain can respond appropriately to digestive irritants.

Factors Involved in Emesis

  • Various stimuli are known to induce vomiting, including:

    • Ingestion of toxins or pathogens: Such as in cases of gastroenteritis, this is a primary physiological trigger of emesis.

    • Mechanical stimulation: Trauma or ischemia in the gastrointestinal tract can also lead to emesis. Surgical intervention may sometimes inadvertently activate these pathways, prompting vomiting as a response.

    • Drug-induced emesis: Certain medications such as chemotherapeutic agents (cytotoxics), Parkinson's medications (levodopa), and other drugs (e.g., opioids, digoxin) can directly stimulate the emetic pathways in the CTZ or the vomiting center.

Neurotransmitter Involvement

  • Several key neurotransmitters play significant roles in the emetic response, including:

    • Dopamine (D2): Primarily involved in the CTZ response.

    • Acetylcholine (ACh): Acts on muscarinic receptors and is involved in signaling from the vestibular system.

    • Serotonin (5-HT): Released in the gut and primarily acts via 5-HT3 receptors in both the CTZ and vagal afferents, significantly involved in the response to chemotherapy.

    • Histamine (H1): Influences the vomiting sensation and response following motion disturbance.

    • Substance P: This neuropeptide plays a crucial role in transmitting pain and emesis signals and acts on NK1 receptors in the vomiting center.

    • Endorphins: May modulate the pain aspect associated with emesis.

  • The CTZ processes inputs from:

    • Bloodborne substances, including hormones, metabolic byproducts, toxins, and drugs.

    • Vagal afferents originating from the gastrointestinal tract, providing critical feedback.

    • Vestibular nuclei involved with balance perception, thereby controlling motion-related emesis.

The Vomiting Reflex

  • The vomiting reflex is primarily governed by:

    • Efferent impulses: which stimulate the contraction of abdominal and diaphragm muscles, creating intragastric pressure that propels contents up the esophagus and out of the mouth.

  • Accompanying symptoms of the vomiting reflex often include:

    • Autonomic responses: such as hypersalivation, sweating, tachycardia, and rapid breathing, all mediated by the autonomic nervous systems. These responses reflect a systemic reaction to the act of vomiting and may vary in intensity based on the trigger.

Antiemetic Pharmacology

  • The effectiveness of antiemetics lies in their mechanism of action, which typically involves blocking specific neurotransmitter receptors implicated in emesis. Choosing an appropriate antiemetic agent necessitates a comprehensive assessment of the underlying cause and type of nausea/vomiting, as well as understanding the patient's individual response to treatments.

Classes of Antiemetics

  • Anticholinergics (e.g., Hyoscine Hydrobromide):

    • Primarily employed in the treatment of motion sickness, these agents work as competitive antagonists against muscarinic receptors (M1) in the CNS and peripheral tissues.

    • Potential CNS side effects may include confusion, dry mouth, and dizziness, particularly in the elderly or those with underlying conditions affecting CNS function.

  • Sedating Antihistamines (e.g., Promethazine, Dimenhydrinate):

    • These medications block histamine H1 receptors in the CNS, effectively reducing nausea and providing sedation.

    • While effective for motion-induced nausea, they have limited efficacy against directly stimulating the CTZ and may lead to anticholinergic effects such as sedation and confusion.

  • Dopamine Receptor Antagonists (e.g., Prochlorperazine, Metoclopramide):

    • This class of medication is generally reserved for short-term use due to the risk of extrapyramidal side effects, which can lead to movement disorders.

    • Prochlorperazine is particularly noted for its effectiveness in treating migraines and certain GI disorders, while Metoclopramide enhances gastric emptying and serves as a prokinetic agent.

  • Serotonin Receptor Antagonists (e.g., Ondansetron, Granisetron):

    • These agents selectively block 5-HT3 serotonin receptors in the CTZ and vagal terminals, making them ideal for managing nausea associated with chemotherapy and radiation therapy.

    • Common side effects include constipation and headache, and they can be used in combination with steroids for enhanced efficacy.

  • NK-1 Receptor Antagonists (e.g., Aprepitant):

    • This class works by blocking substance P receptors in the CTZ and GI tract, effectively preventing severe nausea and vomiting related to chemotherapy.

    • Aprepitant is often prescribed alongside other antiemetics to optimize control of anticipatory, acute, and delayed emesis following chemotherapy.

Conclusion

  • A deep understanding of the neurotransmitters involved and the mechanisms of emesis is vital for clinicians in selecting effective antiemetic therapies. By customizing treatment based on the underlying mechanism provoking nausea or vomiting, healthcare providers can improve patient outcomes, minimizing discomfort and complications associated with this common symptom.